These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19125417)

  • 1. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
    Hansel DE; Nakayama M; Luo J; Abukhdeir AM; Park BH; Bieberich CJ; Hicks JL; Eisenberger M; Nelson WG; Mostwin JL; De Marzo AM
    Prostate; 2009 May; 69(6):603-9. PubMed ID: 19125417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
    Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
    J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
    Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate.
    Heaphy CM; Haffner MC; Graham MK; Lim D; Davis C; Corey E; Epstein JI; Eisenberger MA; Wang H; De Marzo AM; Meeker AK; Lotan TL
    Hum Pathol; 2020 Jul; 101():70-79. PubMed ID: 32389660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of prostatic small-cell neuroendocrine carcinoma.
    Clegg N; Ferguson C; True LD; Arnold H; Moorman A; Quinn JE; Vessella RL; Nelson PS
    Prostate; 2003 Apr; 55(1):55-64. PubMed ID: 12640661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma.
    Li Z; Sun Y; Chen X; Squires J; Nowroozizadeh B; Liang C; Huang J
    Mol Cancer Res; 2015 Mar; 13(3):584-91. PubMed ID: 25512615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: Histological features for accurate diagnosis and toward future novel therapies.
    Ida A; Okubo Y; Kasajima R; Washimi K; Sato S; Yoshioka E; Osaka K; Suzuki T; Yamamoto Y; Yokose T; Kishida T; Miyagi Y
    Pathol Res Pract; 2022 Jan; 229():153731. PubMed ID: 34952423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.
    Chedgy EC; Vandekerkhove G; Herberts C; Annala M; Donoghue AJ; Sigouros M; Ritch E; Struss W; Konomura S; Liew J; Parimi S; Vergidis J; Hurtado-Coll A; Sboner A; Fazli L; Beltran H; Chi KN; Wyatt AW
    J Pathol; 2018 Oct; 246(2):244-253. PubMed ID: 30015382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
    Wang W; Epstein JI
    Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
    Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
    BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
    Tan HL; Sood A; Rahimi HA; Wang W; Gupta N; Hicks J; Mosier S; Gocke CD; Epstein JI; Netto GJ; Liu W; Isaacs WB; De Marzo AM; Lotan TL
    Clin Cancer Res; 2014 Feb; 20(4):890-903. PubMed ID: 24323898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.
    Alshalalfa M; Liu Y; Wyatt AW; Gibb EA; Tsai HK; Erho N; Lehrer J; Takhar M; Ramnarine VR; Collins CC; Den RB; Schaeffer EM; Davicioni E; Lotan TL; Bismar TA
    Int J Cancer; 2019 Dec; 145(12):3453-3461. PubMed ID: 31125117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and role of Foxa proteins in prostate cancer.
    Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
    Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lineage relationship between prostate adenocarcinoma and small cell carcinoma.
    Kanan AD; Corey E; Vêncio RZN; Ishwar A; Liu AY
    BMC Cancer; 2019 May; 19(1):518. PubMed ID: 31146720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers.
    Simon RA; di Sant'Agnese PA; Huang LS; Xu H; Yao JL; Yang Q; Liang S; Liu J; Yu R; Cheng L; Oh WK; Palapattu GS; Wei J; Huang J
    Hum Pathol; 2009 Feb; 40(2):252-8. PubMed ID: 18835619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
    BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.
    Tsai H; Morais CL; Alshalalfa M; Tan HL; Haddad Z; Hicks J; Gupta N; Epstein JI; Netto GJ; Isaacs WB; Luo J; Mehra R; Vessella RL; Karnes RJ; Schaeffer EM; Davicioni E; De Marzo AM; Lotan TL
    Clin Cancer Res; 2015 Dec; 21(24):5619-29. PubMed ID: 26246306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.
    Chen H; Sun Y; Wu C; Magyar CE; Li X; Cheng L; Yao JL; Shen S; Osunkoya AO; Liang C; Huang J
    Endocr Relat Cancer; 2012 Jun; 19(3):321-31. PubMed ID: 22389383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.
    Park JW; Lee JK; Witte ON; Huang J
    Mod Pathol; 2017 Sep; 30(9):1262-1272. PubMed ID: 28621319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4.
    Sowalsky AG; Kissick HT; Gerrin SJ; Schaefer RJ; Xia Z; Russo JW; Arredouani MS; Bubley GJ; Sanda MG; Li W; Ye H; Balk SP
    Clin Cancer Res; 2017 Jul; 23(14):3823-3833. PubMed ID: 28119368
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.